The Clinical Study Of Taxane And Nedaplatin Neoadjuvant Chemotherapy Followed By Concurrent Chemoradiation For Locoregionally Advanced Nasopharyngeal Carcinoma

Objective The curative effect of chemoradiation for locally advanced nasopharyngeal carcinoma has been clear,however,the effect of taxane and nedaplatin neoadjuvant chemotherapy followed by concurrent chemoradiation is uncertain.This study was designed to compare the efficacy and adverse reactions of taxane and nedaplatin neoadjuvant chemotherapy followed by concurrent chemoradiation in locally advanced nasopharyngeal carcinoma.Methods Patients with locally advanced nasopharyngeal carcinoma(stage?-?A)first diagnosed in anqing hospital affiliated to anhui medical university from January 2012 to December 2014,aged 18-70 years,without serious complications,were selected.Eligible patients were randomly selected to receive one treatmen either neoadjuvant chemotherapy followed by concurrent chemoradiation or concurrent chemoradiotherapy.In the control group,50 patients were treated with the treatment nedaplatin(80mg/m~2d1)chemotherapy from the first day of radiotherapy,3 times per week until the end of radiotherapy.In the experimental group of 52 patients,the treatmen of paclitaxel(135mg/m~2d1)and nedaplatin(80mg/m~2d1)was used to induce chemotherapy,followed by concurrent chemoradiation.The short-term and long-term effects and adverse reactions of the two groups were compared.Results In the experimental group,41 patients had complete remission and 9 patients had partial remission.The total effective rate was 96.2%(total remission:78.9%).Partial relief:17.3 percent).The Control group,26 patients had complete remission and18 patients had partial remission.The total effective rate was 88.0%(total response:52.0%),Some relief:36.0%),the curative effect comparison between the two groups using rank and inspection,difference was statistically significant(P=0.004).In terms of side effects,there was no significant difference in the incidence rates of leukopenia?thrombocytopenia?anemia?hepatic and renal insufficiency?mucosits?dermatitis and vomiting(P>0.05)?The 1?2?3-year total survival rates of observation group were 100.0%,93.7%,84.7%,the 1?2?3-year total survival rates of the control group were 94.0%?85.7%?70.1%.The 1?2?3-year progression-free survival rates of observation group were 98.0%,91.6%,80.4%,The 1?2?3-year progression-free survival rates of the control group were 88.0%?75.1%?67.4%?the differences in progression-free survival rate and total survival rate between the 2 groups were significant(P<0.05).Conclusions The results suggest that neoadjuvant chemotherapy followed by concurrent chemoradiation with paclitaxel and nedaplatin in the treatment of locally advanced nasopharyngeal carcinoma has better short-term and long-term efficacy and tolerable adverse side effects than concurrent chemoradiotherapy.